Study IDs Two New Breast Cancer Genes in Black Women
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
A groundbreaking genetic study identified two novel breast cancer-linked genetic variants in Black South African women.
A new blood test can predict the recurrence of breast cancer in high-risk patients by detecting cancer DNA months or years before relapse.
Scientists developed a saliva test that screens for breast cancer, which is showing promising results in experimental testing.
Invitae announced the results of its study on universal hereditary cancer genetic testing in breast cancer patients in a rural population.
Read MoreBiocartis and APIS Assay Technologies are expanding their collaboration to include the commercialization of the APIS ESR1 Mutations Kit.
Read MoreThe findings suggest the need for continued monitoring of access to breast cancer screening and early diagnosis services.
Read MoreIbex launched an AI-powered solution that aids pathologists in setting a higher standard for accurate HER2 scoring in breast cancer patients.
Read MoreThis computational model makes it possible to predict the genetic risk of developing breast cancer based on genetic profiles.Â
Read MoreNew findings suggest that overdiagnosis may be common among older women who are diagnosed with breast cancer after screening.
Read MoreDevyser LynchFAP and Devyser BRCA PALB2 genetic test kits offer efficient, targeted analysis of genes associated with increased cancer risk.
Read MoreExai Bio is collaborating with Quantum Leap Healthcare Collaborative to broaden the use of its novel, RNA-based liquid biopsy platform.
Read MoreThe Centers for Medicare & Medicaid Services approved Advanced Diagnostic Laboratory Test status for PreludeDx’s DCISionRT test.
Read MoreNatera’s Signatera MRD test has met coverage requirements for adjuvant and recurrence monitoring in patients with breast cancer.
Read MorePreciseDx announced that the NYSDOH approved the PDxBr, an LDT designed to enrich breast cancer grading and improve risk categorization.
Read MoreThe companies are collaborating on a product to aid pathologists with an accurate assessment of HER2 IHC scoring in breast cancer patients.Â
Read MoreThe FDA approved the Guardant360 CDx liquid biopsy test as a companion diagnostic for metastatic breast cancer patients with ESR1 mutations.
Read MoreScientists found a marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
Read MorePreciseDx detailed its digital AI platform, which designed to enrich breast cancer grading and improve risk categorization.
Read More